surpass cvot tirzepatide results Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS-CVOT: Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Through dual GLP-1 and GIP receptor activation, tirzepatide targets metabolic dysfunction while influencing anatomical and inflammatory factors associated with upper airway collapse (17, 18)

Growth hormone secretagogues, like those studied in the CJC-1295/Ipamorelin research guide, target the GH/IGF-1 axis rather than incretin pathways and may be studied alongside GLP-1 class compounds for their complementary effects on body composition

Understanding new weight-loss drugs [Internet]

Here is a realistic week-by-week breakdown based on clinical data and community reports from researchers who have made this transition